Reports Q4 revenue $28.1M, consensus $25.58M. “2025 was an important year for ARS Pharma as we established neffy as a differentiated, scalable epinephrine treatment of choice. We have built a strong base business with initial prescriptions expected to begin renewing in 2026 as product reaches expiration. This shift towards renewals, combined with continued growth in new neffy patients, positions us to accelerate market share expansion,” said Richard Lowenthal, Co-Founder, President and CEO of ARS Pharma.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRY:
- ARS Pharmaceuticals announces CHMP of EMA adopted positive opinion for EURneffy
- ARS Pharmaceuticals announces California eligible for neffyinSchools program
- ARS Pharmaceuticals: Buy Rating Reaffirmed on Improved Competitive Outlook After Aquestive’s Anaphylm Setback
- Regulatory Setbacks for Anaphylm Enhance ARS Pharmaceuticals’ Competitive Position and Support SPRY Buy Rating
- ARS Pharmaceuticals competitor gets FDA deficiency letter, says Raymond James